New drug LYNC-101 enters first human trials for ulcerative colitis
NCT ID NCT07505030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of an experimental drug called LYNC-101 in 50 healthy adults. The drug is given by IV infusion, either as a single dose or multiple doses every 3 weeks. The goal is to see if it is safe and how the body processes it, before testing it in people with ulcerative colitis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LYNC-101 (an experimental drug given by IV infusion)
What this could lead to
If successful, this could lead to a new treatment option for ulcerative colitis, helping control the disease and reduce symptoms.
What could go wrong
This is an early Phase 1 trial in only 50 healthy people, not patients. It primarily checks safety, not effectiveness. Many drugs fail in early testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UC - ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••